Goldberg, S. B., Halmos, B., Florez, N., Iams, W. T., Konduri, K., Le, X., Nguyen, D., Raez, L. E., Riess, J. W., Sabari, J. K., Tu, J. C., Bjork, D., Stigger, N., Patel, S. B., Hulten, A., Xia, K., Cifuentes, P., Shanoon, F., Leipoldt, I., Leal, T. (2026). COPERNICUS, a pragmatic phase 2b study of first-line (1L) subcutaneous (SC) amivantamab (ami) + lazertinib (laz) with supportive care in
                    <i>EGFR</i>
                    -mutated advanced NSCLC: Early safety results.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8613